pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

25,353 catalysts · 5,777 approval · 5,000 device 510k · 4,728 grant · 3,057 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 28 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2022-08-24×clear all
type
  • approval5,777
  • device 510k5,000
  • grant4,728
  • 8k filing3,057
  • device pma2,000
  • device recall2,000
  • recall1,126
  • device adverse event1,000
  • earnings583
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Sep 19, 2022

    21
    ›Sep 21, 2022approval1420d agoGLATOPA (GLATIRAMER ACETATE) — FDA approvalGLATIRAMER ACETATE

    Sponsor: SANDOZ. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →GLATIRAMER ACETATE →fda approvals ↗
    ›Sep 21, 2022approval1420d agoGLATOPA (GLATIRAMER ACETATE) — FDA approvalGLATIRAMER ACETATE

    Sponsor: SANDOZ. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →GLATIRAMER ACETATE →fda approvals ↗
    ›Sep 21, 2022approval1420d agoGLATOPA (GLATIRAMER ACETATE) — FDA approvalGLATIRAMER ACETATE

    Sponsor: SANDOZ. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →GLATIRAMER ACETATE →fda approvals ↗
    ›Sep 21, 2022approval1420d agoGLATOPA (GLATIRAMER ACETATE) — FDA approvalGLATIRAMER ACETATE

    Sponsor: SANDOZ. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →GLATIRAMER ACETATE →fda approvals ↗
    ›Sep 21, 2022approval1420d agoEVRYSDI (RISDIPLAM) — FDA approvalEVRYSDI

    Sponsor: GENENTECH INC. Form: FOR SOLUTION. Route: ORAL

    full page →EVRYSDI →fda approvals ↗
    ›Sep 21, 2022approval1420d agoTRAMADOL HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 21, 2022approval1420d agoTRAMADOL HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 21, 2022approval1420d agoTRAMADOL HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 21, 2022approval1420d agoTRAMADOL HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 21, 2022approval1420d agoTRAMADOL HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 21, 2022approval1420d agoTRAMADOL HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 21, 2022approval1420d agoTRAMADOL HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 21, 2022approval1420d agoTRAMADOL HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 21, 2022approval1420d agoRETEVMO (SELPERCATINIB) — FDA approvalselpercatinib

    Sponsor: ELI LILLY AND CO. Form: CAPSULE. Route: ORAL

    full page →selpercatinib →fda approvals ↗
    ›Sep 21, 2022approval1420d agoRETEVMO (SELPERCATINIB) — FDA approvalselpercatinib

    Sponsor: ELI LILLY AND CO. Form: CAPSULE. Route: ORAL

    full page →selpercatinib →fda approvals ↗
    ›Sep 22, 2022approval1419d agoSULFAMETHOPRIM-DS (SULFAMETHOXAZOLE) — FDA approval

    Sponsor: NOVEL LABS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 22, 2022approval1419d agoSULFAMETHOPRIM-DS (SULFAMETHOXAZOLE) — FDA approval

    Sponsor: NOVEL LABS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 22, 2022approval1419d agoSULFAMETHOPRIM (SULFAMETHOXAZOLE) — FDA approval

    Sponsor: NOVEL LABS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 22, 2022approval1419d agoSULFAMETHOPRIM (SULFAMETHOXAZOLE) — FDA approval

    Sponsor: NOVEL LABS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 23, 2022approval1418d agoSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

    Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →risankizumab →fda approvals ↗
    ›Sep 23, 2022approval1418d agoSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

    Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION

    full page →risankizumab →fda approvals ↗

    Week of Sep 26, 2022

    9
    ›Sep 27, 2022approval1414d agoVYXEOS (CYTARABINE) — FDA approvalMeitheal Pharmaceuticals Inc

    Sponsor: JAZZ PHARMS THERAP. Form: POWDER. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Sep 28, 2022approval

    Week of Oct 3, 2022

    20
    ›Oct 3, 2022approval1408d agoCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalCYLTEZO

    Sponsor: BOEHRINGER INGELHEIM. Form: INJECTABLE. Route: INJECTION

    full page →CYLTEZO →fda approvals ↗
    ›Oct 6, 2022approval
    ← prev
    page 2 of 508
    next →
    1413d ago
    DUPIXENT (DUPILUMAB) — FDA approvaldupilumab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION

    full page →dupilumab →fda approvals ↗
    ›Sep 28, 2022approval1413d agoMIRABEGRON — FDA approvalmirabegron ER

    Sponsor: LUPIN LTD. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →mirabegron ER →fda approvals ↗
    ›Sep 28, 2022approval1413d agoGAVRETO (PRALSETINIB) — FDA approvalRIGEL PHARMACEUTICALS INC

    Sponsor: RIGEL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Sep 29, 2022approval1412d agoDYNA-HEX 4 (CHLORHEXIDINE GLUCONATE) — FDA approvalCoorg Instituite of Dental Sciences

    Sponsor: XTTRIUM. Form: SOLUTION. Route: TOPICAL

    full page →fda approvals ↗
    ›Sep 29, 2022approval1412d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →remdesivir →fda approvals ↗
    ›Sep 30, 2022approval1411d agoVIVITROL (NALTREXONE) — FDA approvalnaltrexone ER

    Sponsor: ALKERMES. Form: FOR SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →naltrexone ER →fda approvals ↗
    ›Sep 30, 2022approval1411d agoLYTGOBI (FUTIBATINIB) — FDA approvalfutibatinib

    Sponsor: TAIHO ONCOLOGY. Form: TABLET. Route: ORAL

    full page →futibatinib →fda approvals ↗
    ›Sep 30, 2022approval1411d agoOMEPRAZOLE — FDA approvalomeprazole DR

    Sponsor: DEXCEL PHARMA. Form: TABLET, DELAYED RELEASE. Route: ORAL

    full page →omeprazole DR →fda approvals ↗
    1405d ago
    ISOTRETINOIN — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: ACTAVIS LABS FL. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 6, 2022approval1405d agoMYORISAN (ISOTRETINOIN) — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: UPSHER SMITH LABS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 6, 2022approval1405d agoCLARAVIS (ISOTRETINOIN) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 6, 2022approval1405d agoISOTRETINOIN — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: UPSHER SMITH LABS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 6, 2022approval1405d agoABSORICA (ISOTRETINOIN) — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: SUN PHARM INDS INC. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 6, 2022approval1405d agoAMNESTEEM (ISOTRETINOIN) — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: MYLAN PHARMS INC. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 6, 2022approval1405d agoCLARAVIS (ISOTRETINOIN) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 6, 2022approval1405d agoABSORICA LD (ISOTRETINOIN) — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: SUN PHARM. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 6, 2022approval1405d agoISOTRETINOIN — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: UPSHER SMITH LABS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 6, 2022approval1405d agoISOTRETINOIN — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: AMNEAL PHARMS NY. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 6, 2022approval1405d agoZENATANE (ISOTRETINOIN) — FDA approvalISOTRETINOIN

    Sponsor: DR REDDYS LABS LTD. Form: CAPSULE. Route: ORAL

    full page →ISOTRETINOIN →fda approvals ↗
    ›Oct 6, 2022approval1405d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Oct 7, 2022approval1404d agoTROKENDI XR (TOPIRAMATE) — FDA approvalSUPERNUS PHARMACEUTICALS, INC.

    Sponsor: SUPERNUS PHARMS. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 7, 2022approval1404d agoFUROSCIX (FUROSEMIDE) — FDA approvalFurosemide Sun

    Sponsor: SCPHARMACEUTICALS. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →Furosemide Sun →fda approvals ↗
    ›Oct 7, 2022approval1404d agoTRIUMEQ (ABACAVIR SULFATE) — FDA approvalViiV Healthcare Company

    Sponsor: VIIV HLTHCARE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 7, 2022approval1404d agoTIVICAY (DOLUTEGRAVIR SODIUM) — FDA approvalViiV Healthcare Company

    Sponsor: VIIV HLTHCARE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 7, 2022approval1404d agoTIVICAY PD (DOLUTEGRAVIR SODIUM) — FDA approvalViiV Healthcare Company

    Sponsor: VIIV HLTHCARE. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 7, 2022approval1404d agoTRIUMEQ PD (ABACAVIR SULFATE) — FDA approvalViiV Healthcare Company

    Sponsor: VIIV HLTHCARE. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 7, 2022approval1404d agoJULUCA (DOLUTEGRAVIR SODIUM) — FDA approvalViiV Healthcare Company

    Sponsor: VIIV HLTHCARE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    $AMRX17.88-1.43%
    $AMRX17.88-1.43%
    $AMRX17.88-1.43%
    $AMRX17.88-1.43%
    $LLY1231.94+3.90%
    $AMRX17.88-1.43%
    $AMRX17.88-1.43%
    $AMRX17.88-1.43%
    $AMRX17.88-1.43%
    $LLY1231.94+3.90%
    $ABBV247.97+0.78%
    $ABBV247.97+0.78%
    $RIGL
    $REGN808.05+3.02%
    $RDY12.15-0.57%
    $GILD133.06-0.11%
    $ALKS49.40+0.47%
    $SUPN47.07-1.20%